Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trebananib + sorafenib
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination regimen of **trebananib** and **sorafenib**. Trebananib is a peptibody that binds and neutralizes angiopoietins 1 and 2, blocking their interaction with the Tie2 receptor and thereby inhibiting angiogenesis. Sorafenib is a small molecule kinase inhibitor that targets several tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), RAF kinases, and others, leading to inhibition of tumor cell proliferation and angiogenesis. This combination has been studied mainly in advanced cancers such as renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Clinical studies show generally acceptable safety profiles for the combination, but efficacy results do not demonstrate improved progression-free survival versus sorafenib monotherapy in HCC.
- Brand names
- Nexavar
- Other names
- trebananibsorafenibAMG 386AMG386AMG-386BAY 43-9006BAY43-9006BAY-43-9006
02
Targets
ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TEK (Tie2)
Beyond the preview
Go deeper on trebananib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trebananib + sorafenib.